Cost effectiveness of melanoma in situ resection and repair by dermatology compared to non-dermatology specialties at a single institution

被引:2
|
作者
Burningham, Kevin M. [1 ]
Le, Kim [1 ]
He, Annie [1 ]
O'Brian, Madeleine [1 ]
Shi, Kevin [2 ]
Srivastava, Divya [2 ]
Nijhawan, Rajiv, I [2 ]
机构
[1] Univ Texas Southwestern Med Ctr Dallas, Univ Texas Southwestern Med Sch, Dallas, TX 75390 USA
[2] Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, 5939 Harry Hines Blvd,4th Floor,Suite 100, Dallas, TX 75390 USA
关键词
Mohs micrographic surgery; Wide local excision; Melanoma in situ; Costs and cost analysis; MOHS MICROGRAPHIC SURGERY;
D O I
10.1007/s00403-022-02405-4
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Melanoma-in-situ (MIS) is treated with surgical resection by many specialties. Dermatologists perform these procedures in outpatient settings while others often employ operating rooms and general anesthesia. We hypothesized that MIS managed by dermatology was less costly than that managed by other specialties. All cases of MIS treated at our institution over a 3-year period were evaluated retrospectively for demographic and clinical characteristics and categorized by treating specialty. Estimated cost information was determined using records of charges billed. The mean total cost for MIS treated with wide local excision (WLE) by dermatologists was $1089 (CI = $941-1237) versus all other specialties at $5172 (CI = $2419-7925) (p < 0.001). MIS treated with Mohs micrographic surgery and repaired by dermatology (mean = $2325, CI = $2241-2409) was also less expensive than MIS treated by other specialties with WLE (p < 0.001). The results suggest MIS is significantly less costly to patients and the health care system when treatment is performed by dermatologists compared to other surgical specialties. This is likely due to dermatologists performing the procedures in less expensive outpatient settings.
引用
收藏
页码:661 / 663
页数:3
相关论文
共 8 条
  • [1] Cost effectiveness of melanoma in situ resection and repair by dermatology compared to non-dermatology specialties at a single institution
    Kevin M. Burningham
    Kim Le
    Annie He
    Madeleine O’Brian
    Kevin Shi
    Divya Srivastava
    Rajiv I. Nijhawan
    Archives of Dermatological Research, 2023, 315 : 661 - 663
  • [2] The Need for Increased Melanoma Awareness among Non-dermatology Secondary Care Colleagues
    Quinlan, Catherine
    McCracken, Stephen
    Tierney, Emma
    Heffron, Cynthia
    Fitzgibbon, James
    Murphy, Conleth
    Bourke, John F.
    Murphy, Michelle
    ACTA DERMATO-VENEREOLOGICA, 2019, 99 (07) : 693 - 694
  • [3] Majority of the most-cited articles on cutaneous malignant melanoma are published in non-dermatology/melanoma specialized journals
    Tas, Faruk
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (02) : 612 - 615
  • [4] Accuracy of non-melanoma skin cancer clinical diagnosis compared to single-read histopathologic diagnosis among three independent dermatology practices
    Aeruva, A.
    Rock, J.
    Clarke, L.
    Nguyen, A.
    Xayavong, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : S26 - S26
  • [5] COST-EFFECTIVENESS OF SURVEILLANCE OF STAGE-I MELANOMA - A RETROSPECTIVE APPRAISAL BASED ON A 10-YEAR EXPERIENCE IN A DERMATOLOGY DEPARTMENT IN FRANCE
    BASSERES, N
    GROB, JJ
    RICHARD, MA
    THIRION, X
    ZAROUR, H
    NOE, C
    COLLETVILETTE, AM
    LOTA, I
    BONERANDI, JJ
    DERMATOLOGY, 1995, 191 (03) : 199 - 203
  • [6] The Cost-Effectiveness of Single-Row Compared with Double-Row Arthroscopic Rotator Cuff Repair
    Genuario, James W.
    Donegan, Ryan P.
    Hamman, Daniel
    Bell, John-Erik
    Boublik, Martin
    Schlegel, Theodore
    Tosteson, Anna N. A.
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2012, 94A (15): : 1369 - 1377
  • [7] Effectiveness of interdisciplinary combined dermatology-gastroenterology-rheumatology clinical care compared to usual care in patients with immune-mediated inflammatory diseases: a parallel group, non-blinded, pragmatic randomised trial
    Hjuler, Kasper Fjellhaugen
    Dige, Anders
    Agnholt, Jorgen
    Laurberg, Trine Bay
    Loft, Anne Gitte
    Moller, Louise Faurskov
    Christensen, Robin
    Iversen, Lars
    BMJ OPEN, 2021, 11 (04):
  • [8] COST-EFFECTIVENESS OF DABRAFENIB AND TRAMETINIB COMPARED TO PEMBROLIZUMAB AS ADJUVANT TREATMENT OF STAGE III HIGH-RISK BRAF V600E MUTATION-POSITIVE MELANOMA AFTER SURGICAL RESECTION: A BRAZILIAN PRIVATE PAYER PERSPECTIVE
    Buehler, A.
    Kim, H. S. J.
    Fahham, L.
    Castilho, G.
    VALUE IN HEALTH, 2019, 22 : S451 - S451